TY - JOUR
T1 - High Prevalence of Pneumothorax on PET-CT Studies Performed in Lung Cancer Patients Following Post-Transthoracic Needle Biopsy Mandates Careful Scrutiny
AU - Sommerfeldt, Joseph
AU - Miao, Timothy L.
AU - Zuckier, Lionel Sydney
AU - Gupta, Ashish
PY - 2017/8/1
Y1 - 2017/8/1
N2 - In our practice, FDG PET-CT studies are frequently performed within days of transthoracic needle biopsy, often revealing presence of pneumothorax (PTX), a "critical finding" that should be reported expeditiously. In our experience, prevalence of PTX at PET-CT performed 1 day following biopsy is greater than 40%. Of these, approximately a third are not visible on the postprocedure chest radiography, as in a case we describe. A high level of vigilance is therefore recommended to identify PTX in patients who have undergone recent transthoracic needle biopsy, even when no PTX is present immediately following the biopsy procedure.
AB - In our practice, FDG PET-CT studies are frequently performed within days of transthoracic needle biopsy, often revealing presence of pneumothorax (PTX), a "critical finding" that should be reported expeditiously. In our experience, prevalence of PTX at PET-CT performed 1 day following biopsy is greater than 40%. Of these, approximately a third are not visible on the postprocedure chest radiography, as in a case we describe. A high level of vigilance is therefore recommended to identify PTX in patients who have undergone recent transthoracic needle biopsy, even when no PTX is present immediately following the biopsy procedure.
UR - http://www.scopus.com/inward/record.url?scp=85020247849&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85020247849&partnerID=8YFLogxK
U2 - 10.1097/RLU.0000000000001716
DO - 10.1097/RLU.0000000000001716
M3 - Article
C2 - 28590297
AN - SCOPUS:85020247849
SN - 0363-9762
VL - 42
SP - 637
EP - 638
JO - Clinical Nuclear Medicine
JF - Clinical Nuclear Medicine
IS - 8
ER -
